News Release Details

Talaris Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

February 11, 2022

BOSTON and LOUISVILLE, Ky., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 8:40 AM ET.

A live webcast of the fireside chat will be available on the investors section of the Talaris website at www.talaristx.com. After the live webcast, the event will remain archived on the Talaris website for 30 days.

About Talaris Therapeutics
Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders. Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX.

Media Contact
Marin Bergman
Ten Bridge Communications
marin@tenbridgecommunications.com
(818) 516-2746

Investor Contact
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com 
(339) 970-2843

 


Print Page
RSS Feeds
Email Alerts
Email Page